Literature DB >> 19519371

Detection of clonal immunoglobulin and T-cell receptor gene recombination in hematological malignancies: monitoring minimal residual disease.

Herbert García-Castillo1, Patricio Barros-Núñez.   

Abstract

A considerable number of studies on hematological malignancies have recently demonstrated that the identification of rearrangements in immunoglobulin (Ig) and T-cell receptor (TCR) genes are important tools for diagnosis and follow-up of B- and T-cell disorders. The heterogeneity of these malignancies makes it difficult to carry out a precise assessment in all patients despite well-established morphological and immunophenotyping criteria. Clonal analysis of hematological malignancies is supported by the fact that all malignant cells have a common clonal origin with identically rearranged Ig and/or TCR genes. Identification of B- or T-cell clonality in polyclonal tissue such as the blood is indicative of a lymphoproliferative process. Germline gene segments of Ig heavy chain (IGH), Ig kappa (IGK), Ig lambda (IGL) and TCR are rearranged in each lymphocyte during B- and T-cell differentiation. A specific combination of gene segments and somatic mutations occurring during this process is responsible for the wide diversity of antigen-specific receptors and antibodies. Ig and TCR rearrangements are considered the "fingerprint" of each lymphocyte and therefore can be used as tumor-specific PCR targets for detection of residual malignant cells present after treatment. Determination of minimal residual disease (MRD) has a proven prognostic value and enables effective early interventional treatment. This is becoming routinely implemented in several treatment protocols and is increasingly used in guidelines for drug therapy and stem cell transplantation. In this review we focus on: (1) the process of gene rearrangements in B- and T-cells, (2) principles of polymerase chain reaction (PCR)-based assays and real-time PCR methods commonly used to detect and follow clonal Ig and TCR rearrangements, (3) multiplex primer sets recently designed by the BIOMED-2 concerted action group, and (4) application of these techniques in MRD detection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519371     DOI: 10.2174/187152909788488627

Source DB:  PubMed          Journal:  Cardiovasc Hematol Disord Drug Targets        ISSN: 1871-529X


  5 in total

1.  Asymptomatic circulating T-cell clone cause renal polymorphic inflammatory fibrosis.

Authors:  David Ribes; Audrey Casemayou; Hélène El Hachem; Camille Laurent; Céline Guilbeau-Frugier; François Vergez; Suzanne Tavitian; Joost P Schanstra; Dominique Chauveau; Jean-Loup Bascands; Loïc Ysebaert; Stanislas Faguer
Journal:  Clin Exp Nephrol       Date:  2016-12-26       Impact factor: 2.801

2.  Phenotypes and clinical significance of circulating CD4(+)CD25(+) regulatory T cells (Tregs) in patients with acute-on-chronic liver failure (ACLF).

Authors:  Jiezuan Yang; Ping Yi; Li Wei; Zherong Xu; Yunbo Chen; Lingling Tang; Lanjuan Li
Journal:  J Transl Med       Date:  2012-09-15       Impact factor: 5.531

Review 3.  Next-generation sequencing for MRD monitoring in B-lineage malignancies: from bench to bedside.

Authors:  Xinyue Deng; Meilan Zhang; Jianfeng Zhou; Min Xiao
Journal:  Exp Hematol Oncol       Date:  2022-09-03

4.  Analysis of immunoglobulin and T cell receptor gene rearrangement in the bone marrow of lymphoid neoplasia using BIOMED-2 multiplex polymerase chain reaction.

Authors:  Soyoung Shin; Ah Hyun Kim; Joonhong Park; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Sun Ah Lee; Seok-Goo Cho
Journal:  Int J Med Sci       Date:  2013-08-31       Impact factor: 3.738

5.  Immunoglobulin Heavy Chain Gene Rearrangements in Patients with Gaucher Disease.

Authors:  Predrag Rodić; Milan Lakočević; Sonja Pavlović; Teodora Karan Đurašević; Tatjana Kostić; Nada Suvajdžić Vuković; Zorica Šumarac; Milan Petakov; Dragana Janić
Journal:  J Med Biochem       Date:  2018-07-01       Impact factor: 3.402

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.